Do cell surface trafficking impairments account for variable cell surface sodium iodide symporter levels in breast cancer?

被引:18
作者
Beyer, S. J. [2 ]
Jimenez, R. E. [3 ]
Shapiro, C. L. [4 ]
Cho, J. Y. [5 ,6 ]
Jhiang, S. M. [1 ]
机构
[1] Ohio State Univ, Dept Physiol & Cell Biol, Columbus, OH 43210 USA
[2] Ohio State Univ, Integrated Biomed Sci Grad Program, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA
[4] Ohio State Univ, Div Hematol & Oncol, Coll Med, Columbus, OH 43210 USA
[5] Kyungpook Natl Univ, Dept Biochem, Sch Dent, Taegu, South Korea
[6] Kyungpook Natl Univ, IHBR, Taegu, South Korea
关键词
Breast cancer; Glycoprotein; Iodide uptake; Radionuclide imaging and therapy; Sodium iodide symporter (NIS); SODIUM/IODIDE SYMPORTER; EXPRESSION; RADIOIODIDE; TRANSPORTER; ANTIBODIES; CLONING; GENE;
D O I
10.1007/s10549-008-0059-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The Na+/I- symporter (NIS) is a transmembrane glycoprotein that mediates iodide uptake into thyroid follicular cells and serves as the molecular basis of radioiodine imaging and therapy for thyroid cancer patients. The finding that NIS protein is present in 80-90% of breast tumors suggests that breast cancer patients may also benefit from NIS-mediated radionuclide imaging and targeted therapy. However, only 17-25% of NIS-positive breast tumors have detectable radionuclide uptake activity. The discrepancy between NIS expression and radionuclide uptake activity is most likely contributed by variable cell surface NIS protein levels. Apart from the prevalent view that NIS cell surface trafficking impairments account for the variability, our current study proposes that differential levels of NIS expression may also account for variable cell surface NIS levels among breast tumors. We address the need to confirm the identity of intracellular NIS staining to reveal the mechanisms underlying variable cell surface NIS levels. In addition, we warrant a quantitative correlation between cell surface NIS levels and radionuclide uptake activity in patients such that the cell surface NIS levels required for radionuclide imaging can be defined and the defects impairing NIS activity can be recognized.
引用
收藏
页码:205 / 212
页数:8
相关论文
共 21 条
[1]
Monoclonal antibodies against the human sodium iodide symporter: utility for immunocytochemistry of thyroid cancer [J].
Castro, MR ;
Bergert, ER ;
Beito, TG ;
Roche, PC ;
Ziesmer, SC ;
Jhiang, SM ;
Goellner, JR ;
Morris, JC .
JOURNAL OF ENDOCRINOLOGY, 1999, 163 (03) :495-504
[2]
Cloning and characterization of the thyroid iodide transporter [J].
Dai, G ;
Levy, O ;
Carrasco, N .
NATURE, 1996, 379 (6564) :458-460
[3]
ESKIN BA, 1974, OBSTET GYNECOL, V44, P398
[4]
An immunohistochemical study of Na+/I- symporter in human thyroid tissues and salivary gland tissues [J].
Jhiang, SM ;
Cho, JY ;
Ryu, KY ;
DeYoung, BR ;
Smanik, PA ;
McGaughy, VR ;
Fischer, AH ;
Mazzaferri, EL .
ENDOCRINOLOGY, 1998, 139 (10) :4416-4419
[5]
Tissue iodine content and serum-mediated 125I uptake-blocking activity in breast cancer [J].
Kilbane, MT ;
Ajjan, RA ;
Weetman, AP ;
Dwyer, R ;
McDermott, EWM ;
O'Higgins, NJ ;
Smyth, PPA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (03) :1245-1250
[6]
Signaling through 3′,5′-cyclic adenosine monophosphate and phosphoinositide-3 kinase induces sodium/iodide symporter expression in breast cancer [J].
Knostman, KAB ;
Cho, JY ;
Ryu, KY ;
Lin, XQ ;
McCubrey, JA ;
Hla, T ;
Liu, CH ;
Di Carlo, E ;
Keri, R ;
Zhang, M ;
Hwang, DY ;
Kisseberth, WC ;
Capen, CC ;
Jhiang, SM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (10) :5196-5203
[7]
PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer [J].
Knostman, Katherine A. B. ;
McCubrey, James A. ;
Morrison, Carl D. ;
Zhang, Zhaoxia ;
Capen, Charles C. ;
Jhiang, Sissy M. .
BMC CANCER, 2007, 7 (1)
[8]
Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line [J].
Kogai, T ;
Schultz, JJ ;
Johnson, LS ;
Huang, M ;
Brent, GA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (15) :8519-8524
[9]
Current approaches to primary therapy for papillary and follicular thyroid cancer [J].
Mazzaferri, EL ;
Kloos, RT .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (04) :1447-1463
[10]
Moon DH, 2001, NUCL MED BIOL, V28, P829